Deksloksiglumid (Serbian Wikipedia)
Analysis of information sources in references of the Wikipedia article "Deksloksiglumid" in Serbian language version.
refsWebsite
Global rank
Serbian rank
11th place
23rd place
doi.org
- Cremonini, F.; Camilleri, M.; McKinzie, S.; Carlson, P.; Camilleri, C. E.; Burton, D.; Thomforde, G.; Urrutia, R.; Zinsmeister, A. R. (2005). „Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: A pharmacodynamic and pharmacogenomic study”. The American Journal of Gastroenterology. 15743365 (3): 652—663. PMID 15743365. S2CID 34227592. doi:10.1111/j.1572-0241.2005.41081.x.
- Galligan, J. J.; Vanner, S. (2005). „Basic and clinical pharmacology of new motility promoting agents”. Neurogastroenterology and Motility. 16185302 (5): 643—653. PMID 16185302. S2CID 7298061. doi:10.1111/j.1365-2982.2005.00675.x.
- Roberts, D. J.; Banh, H. L.; Hall, R. I. (2006). „Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients”. Current Opinion in Critical Care. 16810038 (4): 295—302. PMID 16810038. S2CID 32307333. doi:10.1097/01.ccx.0000235205.54579.5d.
- Barrett, T. D.; Yan, W.; Freedman, J. M.; Lagaud, G. J.; Breitenbucher, J. G.; Shankley, N. P. (2008). „Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction”. British Journal of Pharmacology. 18297100 (8): 1650—1658. PMC 2438255
. PMID 18297100. doi:10.1038/bjp.2008.44.
nih.gov
ncbi.nlm.nih.gov
- Cremonini, F.; Camilleri, M.; McKinzie, S.; Carlson, P.; Camilleri, C. E.; Burton, D.; Thomforde, G.; Urrutia, R.; Zinsmeister, A. R. (2005). „Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: A pharmacodynamic and pharmacogenomic study”. The American Journal of Gastroenterology. 15743365 (3): 652—663. PMID 15743365. S2CID 34227592. doi:10.1111/j.1572-0241.2005.41081.x.
- Galligan, J. J.; Vanner, S. (2005). „Basic and clinical pharmacology of new motility promoting agents”. Neurogastroenterology and Motility. 16185302 (5): 643—653. PMID 16185302. S2CID 7298061. doi:10.1111/j.1365-2982.2005.00675.x.
- Roberts, D. J.; Banh, H. L.; Hall, R. I. (2006). „Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients”. Current Opinion in Critical Care. 16810038 (4): 295—302. PMID 16810038. S2CID 32307333. doi:10.1097/01.ccx.0000235205.54579.5d.
- Maselli, M. A.; Mennuni, L. (2003). „CCK1 receptor antagonist, dexloxiglumide: Effects on human isolated gallbladder. Potential clinical applications”. Minerva Gastroenterologica e Dietologica. 16484960 (3): 211—216. PMID 16484960.
- Barrett, T. D.; Yan, W.; Freedman, J. M.; Lagaud, G. J.; Breitenbucher, J. G.; Shankley, N. P. (2008). „Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction”. British Journal of Pharmacology. 18297100 (8): 1650—1658. PMC 2438255 . PMID 18297100. doi:10.1038/bjp.2008.44.
semanticscholar.org
api.semanticscholar.org
- Cremonini, F.; Camilleri, M.; McKinzie, S.; Carlson, P.; Camilleri, C. E.; Burton, D.; Thomforde, G.; Urrutia, R.; Zinsmeister, A. R. (2005). „Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: A pharmacodynamic and pharmacogenomic study”. The American Journal of Gastroenterology. 15743365 (3): 652—663. PMID 15743365. S2CID 34227592. doi:10.1111/j.1572-0241.2005.41081.x.
- Galligan, J. J.; Vanner, S. (2005). „Basic and clinical pharmacology of new motility promoting agents”. Neurogastroenterology and Motility. 16185302 (5): 643—653. PMID 16185302. S2CID 7298061. doi:10.1111/j.1365-2982.2005.00675.x.
- Roberts, D. J.; Banh, H. L.; Hall, R. I. (2006). „Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients”. Current Opinion in Critical Care. 16810038 (4): 295—302. PMID 16810038. S2CID 32307333. doi:10.1097/01.ccx.0000235205.54579.5d.